{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Medicamen Biotech Ltd
Medicamen Biotech Ltd Shows Mixed Technical Signals Amid Price Momentum Shift
Medicamen Biotech Ltd has experienced a notable shift in price momentum, reflected in a 9.09% gain on 8 Jan 2026, signalling a potential technical turnaround. However, the stock’s broader technical indicators present a complex picture, with mixed signals from MACD, RSI, moving averages and other momentum oscillators, suggesting cautious optimism for investors in the Pharmaceuticals & Biotechnology sector.
Medicamen Biotech Ltd is Rated Sell
Medicamen Biotech Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 12 Aug 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 02 January 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.
Medicamen Biotec Sees Revision in Market Assessment Amid Mixed Financial Signals
Medicamen Biotec, a microcap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting nuanced shifts across key financial and technical parameters. This adjustment comes amid a backdrop of mixed performance indicators and ongoing challenges in the company’s long-term growth trajectory.
Why is Medicamen Biotec falling/rising?
On 12-Dec, Medicamen Biotech Ltd witnessed a notable uptick in its share price, rising by 3.53% to close at ₹404.40. This movement comes despite the company’s challenging longer-term performance relative to benchmark indices, highlighting a complex market dynamic influencing the stock.
Medicamen Biotec Sees Revision in Market Evaluation Amid Mixed Financial Signals
Medicamen Biotec, a microcap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting nuanced shifts across key financial and technical parameters. This adjustment comes amid a backdrop of mixed performance indicators and valuation considerations that investors should carefully analyse.
Medicamen Biotech Reports Strong Profit Growth Amidst Operational Efficiency Challenges
Medicamen Biotech reported a significant increase in profit after tax for the quarter ending September 2025, reaching Rs 2.67 crore. The company also achieved its highest cash and cash equivalents at Rs 43.68 crore and net sales of Rs 47.17 crore, although it faces challenges with low return on capital employed and debtor turnover.
Medicamen Biotech Q2 FY26: Profit Surge Masks Deeper Margin Concerns
Medicamen Biotech Ltd., a research-led pharmaceutical company with operations spanning over 40 countries, reported a consolidated net profit of ₹2.67 crores for Q2 FY26, marking an impressive 82.88% year-on-year surge from ₹1.46 crores in the corresponding quarter last year. The sequential improvement was equally robust, with profits climbing 24.19% from ₹2.15 crores in Q1 FY26. However, the stock has struggled to capitalise on this operational momentum, declining 15.50% over the past year whilst the Sensex advanced 9.48%, resulting in a negative alpha of 24.98 percentage points.
Is Medicamen Biotec overvalued or undervalued?
As of November 14, 2025, Medicamen Biotec is considered expensive and overvalued with a PE ratio of 58.40 and an EV to EBITDA of 38.85, despite a slight improvement in valuation grade, as evidenced by its poor stock performance of -19.84% year-to-date compared to the Sensex's 8.22% gain.
Is Medicamen Biotec overvalued or undervalued?
As of November 14, 2025, Medicamen Biotec is considered overvalued with a PE ratio of 58.40, significantly higher than peers like Sun Pharma and Cipla, and has underperformed the Sensex with a year-to-date return of -19.84%.
Is Medicamen Biotec overvalued or undervalued?
As of November 14, 2025, Medicamen Biotec is considered expensive with a PE ratio of 58.40 and an EV to EBITDA of 38.85, indicating overvaluation compared to peers and a year-to-date stock performance of -19.84% against the Sensex's 8.22%.
How has been the historical performance of Medicamen Biotec?
Medicamen Biotec's historical performance shows a decline in net sales from 179.31 Cr in March 2024 to 162.55 Cr in March 2025, with a drop in operating profit and profit after tax, while total assets and liabilities slightly increased. Cash flow from operating activities remained negative at -6.00 Cr for both years.
Is Medicamen Biotec overvalued or undervalued?
As of November 13, 2025, Medicamen Biotec is considered very expensive and overvalued, with a PE ratio of 59.70, significantly higher than peers like Sun Pharma and Cipla, and despite a recent short-term gain, it has declined 18.07% year-to-date.
Why is Medicamen Biotec falling/rising?
As of 06-Nov, Medicamen Biotech Ltd's stock price is rising at 396.05, with a recent increase of 2.98%. The stock has shown strong short-term performance, gaining 12.51% over the last five days, but has underperformed year-to-date with a decline of 22.23% compared to the Sensex's gain.
Medicamen Biotech Ltd Gains 20.66% in Last Month Despite 0.14% Decline Today
Medicamen Biotech Ltd is experiencing significant buying interest, particularly in the microcap pharmaceuticals sector. The stock has shown notable short-term gains, outperforming the Sensex. However, its longer-term performance reveals substantial declines over the past year and three years, despite recent positive momentum in trading activity.
Medicamen Biotech Faces Selling Pressure with 30.45% Year-to-Date Loss Amidst Ongoing Declines
Medicamen Biotech Ltd is experiencing significant selling pressure, continuing a trend of losses. The stock has underperformed compared to the Sensex, with a notable decline over the past year. Despite a recent weekly increase, its long-term performance remains weak, reflecting broader market challenges and potential company-specific issues.
Is Medicamen Biotec overvalued or undervalued?
As of October 23, 2025, Medicamen Biotec is considered very expensive with a PE ratio of 52.55 and significantly higher valuation metrics compared to peers like Sun Pharma and Cipla, while also underperforming the Sensex with a year-to-date return of -27.87%.
Why is Medicamen Biotec falling/rising?
As of 23-Oct, Medicamen Biotech Ltd's stock price has risen to Rs 367.30, reflecting a 13.08% increase today, but it has a year-to-date decline of 27.87% and a significant drop of 59.59% over the past three years. Despite strong short-term gains, declining investor participation and long-term volatility may pose risks for future stability.
Medicamen Biotech Ltd Gains 0.46% Today, Reaches Intraday High Amid Recent Buying Trend
Medicamen Biotech Ltd is experiencing increased buying activity, with recent gains aligning closely with the Sensex. While the stock has shown short-term improvements, its long-term performance reveals significant declines over the past year and three years, indicating mixed market sentiment despite current enthusiasm.
Why is Medicamen Biotec falling/rising?
As of 15-Oct, Medicamen Biotech Ltd's stock price is rising to Rs 319.00, up 4.33% after two days of decline, with increased investor interest indicated by a 118.53% rise in delivery volume. Despite this short-term recovery, the stock remains below long-term moving averages and has underperformed over the past month and year.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
